Drug Utilization Review (DUR) Meeting Minutes
April 9, 2019

Members Present: Michael Booth, Gabriela Balf, Tanya Schmidt, Andrea Honeyman, Peter Woodrow, Jesse Rue, Katie Kram, LeNeika Roehrich, Kayli Bardell

Members Absent: Michael Quast, Jeffrey Hostetter, Russ Sobotta, Laura Schield

Medicaid Pharmacy Department: Brendan Joyce, Alexi Murphy

Old Business

Chair L. Roehrich called the meeting to order at 1:07 p.m. Chair L. Roehrich asked for a motion to approve the minutes of the December meeting. P. Woodrow moved that the minutes be approved and K. Kram seconded the motion. Chair L. Roehrich called for a voice vote to approve the minutes. The motion passed with no audible dissent.

Review Top 15 Therapeutic Categories/Top 25 Drugs

B. Joyce presented the quarterly review of the top 15 therapeutic classes by total cost of claims, top 25 drugs based on number of claims, and top 25 drugs based on claims cost for the 4th quarter of 2018.

PDL/PA Criteria Updates

A. Murphy shared with the Board all of changes made to the Preferred Drug List since the most recent version of the Preferred Drug List was posted. Notable changes included removing PA requirements from 7 ACE/ARB containing agents, as well as from QVAR RediHaler, Relistor syringe, Spiriva Respimat, Striverdi Respimat, and trospium. Other notable changes including adding the following agents to PA: colchicine, Dupixent, Emgality, Novolin 70-30 Flexpen, Nystatin-Triamcinolone, Omnaris, Pataday, and Tracleer. When a new version of the PDL is published and posted to the website, all updates/changes made since the last version are called out at the top of the document itself.

Second Review of Orilissa

A motion and second was made at the December meeting to place Orilissa on prior authorization. The topics were brought up for a second review. A. Murphy explained to the board that examples of specific agents would be added to the form for the sake of clarity. Margaret Olman of AbbVie offered to provide the Board with any information they would like regarding Orilissa. Chair L. Roehrich called for a voice vote to approve the presented criteria, and the motion passed with no audible dissent.

Second Review of Vaginal Anti-Infective Agents

A motion and second was made at the December meeting to generate prior authorization criteria for vaginal anti-infective agents. The topic was brought up for a second review. A. Murphy proposed that the Board remove the 30-day requirement listed in the criteria. J. Rue motioned to amend the criteria as suggested and P. Woodrow seconded the motion. There was no public comment. Chair L. Roehrich called for a voice vote on the amended criteria, and the motion passed with no audible dissent.

Second Review of Agents for the Treatment of Glaucoma
A motion and second was made at the December meeting to place agents for the treatment of glaucoma on prior authorization. The topic was brought up for a second review. There was no public comment. Chair L. Roehrich called for a voice vote and the motion passed with no audible dissent.

Second Review of Agents for the Treatment of Dry Eye Syndrome
A motion and second was made at the December meeting to place agents for the treatment of dry eye syndrome on prior authorization. The topic was brought up for a second review. There was no public comment. Chair L. Roehrich called for a voice vote and the motion passed with no audible dissent.

New Business

Review of Estrogen Agents
A. Murphy presented a review of estrogen agents to the Board. A motion was made by J. Rue to create a new PA criteria class and manage these medications through prior authorization. The motion was seconded by K. Kram. This topic will be reviewed at the next meeting.

Review of Sivextro
A. Murphy presented a review of Sivextro to the Board. A motion was made by K. Kram to create PA criteria for the use of this agent and manage this medication through prior authorization. The motion was seconded by A. Honeyman. This topic will be reviewed at the next meeting.

Review of Nuzyra
A. Murphy presented a review of Nuzyra to the Board. A motion was made by P. Woodrow to create PA criteria for the use of this agent and manage this medication through prior authorization. The motion was seconded by K. Kram. This topic will be reviewed at the next meeting.

Agents for Treatment of Osteoporosis
A. Murphy presented a review of agents for treatment of osteoporosis to the Board. A motion was made by J. Rue to create a new PA criteria class and manage these medications through prior authorization. The motion was seconded by K. Kram. This topic will be reviewed at the next meeting.

Agents for Treatment of Hyperkalemia
A. Murphy presented a review of agents for treatment of hyperkalemia to the Board. A motion was made by J. Rue to create a new PA criteria class and manage these medications through prior authorization. The motion was seconded by A. Honeyman. This topic will be reviewed at the next meeting.

Agents for Treatment of Parkinson's Disease
A. Murphy presented a review of agents for treatment of Parkinson's disease to the Board. A motion was made by M. Booth to create a new PA criteria class and manage these medications through prior authorization. The motion was seconded by J. Rue. This topic will be reviewed at the next meeting.

Report on Utilization of Long-Acting Beta Agonist/Inhaled Corticosteroid Inhaler Combination Products Without Use of a Rescue Inhaler

In 2018, a claims processing edit was put in place requiring that patients receiving a long-acting beta agonist/inhaled corticosteroid (LABA/ICS) combination inhaler must also have a paid claim for a rescue inhaler within the past year to ensure the patient has access to a rescue inhaler. To evaluate the effect of this edit, T. DeRuiter presented utilization data showing the number of FFS patients receiving a (LABA/ICS) combination inhaler without having a paid claim for a rescue inhaler within the past year, comparing the number of patients before and after the claims processing edit was put in place. The data showed that only 5 patients are currently receiving a LABA/ICA inhaler without also having paid claims for a rescue inhaler, as compared to 49 patients prior to the edit being put in place.

Report on Utilization of Guideline Supported Use of Metformin

To promote appropriate, guideline supported use of metformin as a first-line agent for patients with diabetes mellitus type 2, a claims processing edit was put in place on preferred DPP-4 inhibitor, GLP-1 agonist, or SGLT-2 inhibitors. The edit requires that, for claims of these preferred agents to pay automatically at the point of sale and not require PA approval, the patient must be currently stable on a metformin-containing agent with good compliance over the past 3 months. To evaluate the impact of this edit, T. DeRuiter presented utilization data showing the number of FFS patients receiving one of these agents without concomitant use of a metformin-containing agent, comparing the number of patients before and after the claims processing edit was put in place. The data showed a reduction in the number of patients receiving one of these agents without metformin for all of these agents with the exception of linagliptin, resulting in 53 fewer patients receiving these medications without using metformin.

Retrospective Drug Utilization Review (RDUR) Criteria Recommendations

The recommended RDUR criteria enclosed in the packet were developed from product information provided by the manufacturers and are usually consistent with new indications, new drugs added, and new warnings. These proposed criteria will be added to the current set of criteria and will be used in future DUR cycles. J. Rue moved to amend the new criteria as stated above and approve it. K. Kram seconded the motion. The motion passed with no audible dissent.

Adjournment and Upcoming Meeting Date

Chair L. Roehrich adjourned the meeting at 2:20 pm. The next DUR Board meeting will be held June 5, 2019 at 1:00 pm at the State Capitol building in the Brynhild -Haugland room.